NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Tabelecleucel for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus ID1203

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company • Pierre Fabre (tabelecleucel) Patient/carer groups • Action for Sick Children • Anthony Nolan • Black Health Agency for Equality • Blood Cancer UK • Cancer Black Care • Cancer Equality • Cancer 52 • Childhood Cancer Parents Alliance • Children with Cancer UK • Contact a Family • DKMS • Helen Rollason Cancer Charity • Independent Cancer Patient Voice • Lymphoma Action • Macmillan Cancer Support • Maggie's Centre • Marie Curie • South Asian Health Foundation • Specialised Healthcare Alliance • Teenage Cancer Trust • Tenovus Cancer Care • Young Lives vs Cancer Professional groups • Association of Cancer Physicians • British Blood Transfusion Society • British Committee for Standards in Haematology • British Geriatrics Society • British Institute of Radiology • British Psychosocial Oncology Society • British Society for Gene and Cell Therapy	General • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee Possible comparator companies • A A H Pharmaceuticals (prednisolone) • Accord Healthcare (doxorubicin) • ADVANZ Pharma (prednisolone) • Almus Pharmaceuticals (prednisolone) • Baxter Healthcare (cyclophosphamide) • Bristol Laboratories (prednisolone) • Genesis Pharmaceuticals (prednisolone) • Hospira UK (vincristine) • Logixx Pharma (prednisolone) • Medac GmbH (doxorubicin) • Napp Pharmaceuticals (rituximab) • Pfizer (doxorubicin, rituximab, vincristine) • Phoenix Labs (prednisolone)

Consultees	Commentators (no right to submit or appeal)
• British Society for Haematology • British Society for Human Genetics • British Society for Immunology • British Society of Blood and Marrow Transplantation • British Transplantation Society • Cancer Research UK • NHS Blood and Transplant • Royal College of General Practitioners • Royal College of Nursing • Royal College of Paediatrics and Child Health • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal College of Surgeons • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • United Kingdom Clinical Pharmacy Association • UK Oncology Nursing Society <u>Others</u> • Department of Health and Social Care • NHS Blackburn with Darwen CCG • NHS England • NHS Wyre Forest CCG • Welsh Government	• Roche (rituximab) • Sandoz Limited (cyclophosphamide, rituximab) • Seacross Pharmaceuticals (doxorubicin) • Strides Pharma (prednisolone) • Wockhardt UK (prednisolone) • Zentiva (prednisolone) <u>Relevant research groups</u> • Cochrane Childhood Cancer Group • Cochrane Haematological Malignancies Group • Cochrane UK • European Group for Blood and Marrow Transplantation • Genomics England • Institute of Cancer Research • Lymphoma Research Trust • MRC Clinical Trials Unit • National Cancer Research Institute • National Institute for Health Research <u>Associated Public Health Groups</u> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement[1], respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.

[1] Non company consultees are invited to submit statements relevant to the group they are representing.